Feasibility of a randomized controlled trial of enteral vs intravenous resuscitation for adults with major burn injuries in Nepal.

Introduction: Enterally-based resuscitation (EResus) is safe, efficacious, and has operational advantages, particularly in low-resource settings. However, there is a lack of real-world effectiveness studies and evidence-based protocols, which hinders implementation. To address this gap, we conducted a feasibility study ahead of a randomized controlled trial (RCT) of enterally based versus usual resuscitation at a tertiary burn center in Nepal which had no prior clinical trial experience.

Micro-nanoscale polystyrene co-exposure impacts the uptake and translocation of arsenic and boscalid by lettuce (Lactuca sativa).

The influence of micro-nanoplastics (MNPs) on the fate and effects of other pollutants present in the environment is largely unknown. This study evaluated if the root exposure to MNPs (polystyrene, PS; 20 or 1000 nm) had an impact on the accumulation of arsenic and boscalid (As and Bos) in lettuce (Lactuca sativa). Under hydroponic conditions, plants were co-exposed to MNPs at 10 or 50 mg/L, and to 1 mg/L of each environmental pollutant (EP).

The Future of Giant Cell Arteritis Diagnosis and Management: A Systematic Review of Artificial Intelligence and Predictive Analytics.

Giant cell arteritis (GCA), a systemic vasculitis affecting large and medium-sized arteries, poses significant diagnostic and management challenges, particularly in preventing irreversible complications like vision loss. Recent advancements in artificial intelligence (AI) technologies, including machine learning (ML) and deep learning (DL), offer promising solutions to enhance diagnostic accuracy and optimize treatment strategies for GCA. This systematic review, conducted according to the PRISMA 2020 guidelines, synthesizes existing literature on AI applications in GCA care, with a focus on diagnostic accuracy, treatment outcomes, and predictive modeling.

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.